Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

SIOG 2024: Updates in radiation oncology

SIOG 2024: Updates in medical oncology

Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India